Journal
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume 34, Issue 11, Pages 861-868Publisher
SPRINGER
DOI: 10.1007/BF03346731
Keywords
Acromegaly; GH deficiency; GH receptor; short stature
Categories
Funding
- Pfizer Italia
Ask authors/readers for more resources
The GH receptor (GHR) plays a key role in the the function of the GH/IGF-I axis and is the major effector of human growth. A common polymorphic variant consisting of genomic exon 3 deletion or retention (d3-GHR and full-length GHR, respectively), described in 2000, has been linked with increased receptor activity due to enhanced signal transduction. Subsequent pharmacogenetic studies have addressed a possible role of GHR polymorphism on the response to recombinant human GH treatment first in short children and then in adults, many of them suggesting that growth response to GH may be influenced, at least in some aspects, by this polymorphism. Similar studies, performed in patients with acromegaly, assumed an influence of the d3-GHR variant in the relationship between GH and IGF-I levels. More recently, some studies have investigated the relation between GHR genotype and treatment with the GHR antagonist pegvisomant, suggesting a better clinical response to therapy related to d3-GHR genotype. This review provides' a summary of the main pharmacogenetic studies performed on this current and still open topic. (J. Endocrinol. Invest. 34: 861-868, 2011) (C)2011, Editrice Kurtis
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available